Savant Capital’s Regencell Bioscience RGC Stock Holding History

Savant Capital’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$114K	Buy	+18,255	New	+$106K	﹤0.01%	2300

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

CIBC Asset Management Toronto, Ontario, Canada $47B AUM 34.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Bare Financial Services Gap, Pennsylvania $447M AUM 11.53% 1-Year Est. Return

Provenance Wealth Advisors Fort Lauderdale, Florida $1.69B AUM 11.53% 1-Year Est. Return

Silver Grove Financial Group Orchard Park, New York $214M AUM 19.83% 1-Year Est. Return

Savant Capital's RGC Position: Q3 2026 in Review

Savant Capital opened a new position in Regencell Bioscience (RGC) in Q3 2026: 18,255 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #2300 among its holdings.

14 funds tracked by Wall St. Rank hold RGC as of Q3 2026.

Savant Capital held 18,255 shares of Regencell Bioscience worth $114K as of Q3 2026.
Regencell Bioscience was a new Savant Capital position in Q3 2026.
Regencell Bioscience made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #2300 holding.
14 funds tracked by Wall St. Rank held Regencell Bioscience as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.